Ambu sets sights on endoscopy growth, shares on Copenhagen exchange

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-28, 09:53.

Ambu (DK0060946788) is a Danish medtech group listed on Nasdaq Copenhagen with a focus on single-use endoscopy and patient monitoring devices. The company’s current strategy centers on expanding its endoscopy platform across respiratory, urology and GI procedures in hospitals worldwide.

Strategic push in single-use endoscopy

Ambu describes itself as a global leader in single-use endoscopy, with more than 2,100 employees and sales in over 100 countries according to its latest corporate profile. The group’s endoscopy portfolio covers bronchoscopy, ENT, urology and GI segments, addressing infection control and workflow efficiency needs in hospital settings.

Management has articulated a long-term strategy focused on converting reusable endoscope procedures to single-use solutions, targeting higher adoption in intensive care units and operating theaters. The company points out that single-use endoscopes can help reduce cross-contamination risk and eliminate reprocessing, an argument that aligns with broader infection-prevention trends in the medtech sector.

Position in the medtech peer group

On the stock market Ambu is part of the Nordic medtech peer group that includes names such as Coloplast and GN Store Nord, even though Ambu’s focus is more specifically on endoscopy and airway management. Investors often compare Ambu’s single-use endoscopy segment with conventional reusable endoscopy players like Olympus and Boston Scientific, where capital equipment and reprocessing services remain central to the business model.

Sector commentary from analysts covering European medtech has highlighted single-use devices as a structural growth niche, supported by hospital hygiene standards and pressures to optimize staff time. Ambu’s positioning in this niche gives the stock a distinct profile versus broader medical-technology indices, even as the company still derives meaningful revenue from traditional patient monitoring and diagnostics products.

The product behind the stock

Ambu’s flagship line in single-use endoscopy is the aScope family of disposable bronchoscopes and related endoscopes for airway and pulmonary procedures. These devices are used alongside visualisation systems to give clinicians a real-time view of the patient’s airways while avoiding the cleaning and reprocessing steps required for reusable equipment.

Where the stock trades today

Ambu shares (DK0060946788) trade on Nasdaq Copenhagen in Danish kroner; the latest live-verified price data and market cap are available via the exchange and the company’s Investor Relations site.

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell Ambu shares or any other securities.